Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leuprolide Acetate 22.5 mg (3-Month Depot) in Prostate Cancer
NCT00076531Phase 3Completed
- Sponsor
- Oakwood Laboratories
- Start
- Dec 2003
- Primary completion
- Nov 2004
- Modality
- Peptides, Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of leuprolide in prostate cancer (PCa), sponsored by Oakwood Laboratories. Primary endpoint: Serum testosterone suppression to castrate levels (≤ 50 ng/dL) at Day 168. Started Dec 2003; status: completed.
02
Drugs
leuprolide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00076531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00076531.